Company Performance Metrics
- Dr. Dror Yeger: Co-Founder & VP of Business Development
- Eran Issler: Chief Information Officer
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy.
Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners.
OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance.
OncoHost was founded in 2017 and is headquartered in Binyamina, Israel.
